A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Overview

About this study

The purpose of this study is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Subjects must have clinically diagnosed STGD1 with at least one mutation identified in the ABCA4 gene.
* Subjects must have a defined aggregate atrophic lesion in 1 or both eyes.
* Minimum BCVA is required in the study eye

Exclusion Criteria:

* Any ocular disease other than STGD1 that, in the opinion of the investigator, would complicate assessment of a treatment effect.
* History of ocular surgery in the study eye in the last 3 months.
* Any prior gene therapy.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/13/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brittni Scruggs, M.D., Ph.D.

Open for enrollment

Contact information:

Laura Taylor C.O.A.

(507) 422-2779

Taylor.Laura2@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20571936

Mayo Clinic Footer